Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

O-linked mucin-type glycosylation in breast cancer.

Burchell JM, Beatson R, Graham R, Taylor-Papadimitriou J, Tajadura-Ortega V.

Biochem Soc Trans. 2018 Aug 20;46(4):779-788. doi: 10.1042/BST20170483. Epub 2018 Jun 14. Review.

2.

Latest developments in MUC1 immunotherapy.

Taylor-Papadimitriou J, Burchell JM, Graham R, Beatson R.

Biochem Soc Trans. 2018 Jun 19;46(3):659-668. doi: 10.1042/BST20170400. Epub 2018 May 21. Review.

3.

JARID1/KDM5 demethylases as cancer targets?

Taylor-Papadimitriou J, Burchell J.

Expert Opin Ther Targets. 2017 Jan;21(1):5-7. Epub 2016 Nov 28. No abstract available.

PMID:
27882807
4.

Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells.

Maher J, Wilkie S, Davies DM, Arif S, Picco G, Julien S, Foster J, Burchell J, Taylor-Papadimitriou J.

Immunity. 2016 Nov 15;45(5):945-946. doi: 10.1016/j.immuni.2016.10.014.

5.

The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.

Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S, Hillier M, Maher J, Noll T, Crocker PR, Taylor-Papadimitriou J, Burchell JM.

Nat Immunol. 2016 Nov;17(11):1273-1281. doi: 10.1038/ni.3552. Epub 2016 Sep 5.

6.

Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.

Karagiannis P, Villanova F, Josephs DH, Correa I, Van Hemelrijck M, Hobbs C, Saul L, Egbuniwe IU, Tosi I, Ilieva KM, Kent E, Calonje E, Harries M, Fentiman I, Taylor-Papadimitriou J, Burchell J, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN.

Oncoimmunology. 2015 Jun 3;4(11):e1032492. eCollection 2015 Nov.

7.

The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL.

Beatson R, Maurstad G, Picco G, Arulappu A, Coleman J, Wandell HH, Clausen H, Mandel U, Taylor-Papadimitriou J, Sletmoen M, Burchell JM.

PLoS One. 2015 May 7;10(5):e0125994. doi: 10.1371/journal.pone.0125994. eCollection 2015.

8.

Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.

Picco G, Beatson R, Taylor-Papadimitriou J, Burchell JM.

Eur J Immunol. 2014 Jul;44(7):1947-55. doi: 10.1002/eji.201344076. Epub 2014 Apr 17.

9.

The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter.

Hasan UA, Zannetti C, Parroche P, Goutagny N, Malfroy M, Roblot G, Carreira C, Hussain I, Müller M, Taylor-Papadimitriou J, Picard D, Sylla BS, Trinchieri G, Medzhitov R, Tommasino M.

J Exp Med. 2013 Jul 1;210(7):1369-87. doi: 10.1084/jem.20122394. Epub 2013 Jun 10.

10.

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.

Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, Ford J, Desai R, David L, Trinder P, Acres B, Schwientek T, Gammerman A, Reis CA, Silva L, Osório H, Hallett R, Wandall HH, Mandel U, Hollingsworth MA, Jacobs I, Fentiman I, Clausen H, Taylor-Papadimitriou J, Menon U, Burchell JM.

Br J Cancer. 2013 May 28;108(10):2045-55. doi: 10.1038/bjc.2013.214. Epub 2013 May 7.

11.

Cyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer.

Sproviero D, Julien S, Burford B, Taylor-Papadimitriou J, Burchell JM.

J Biol Chem. 2012 Dec 28;287(53):44490-7. doi: 10.1074/jbc.M112.427827.

12.

Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers.

Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM.

Cancer Res. 2011 Dec 15;71(24):7683-93. doi: 10.1158/0008-5472.CAN-11-1139. Epub 2011 Oct 24.

13.

Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation.

Pinto R, Carvalho AS, Conze T, Magalhães A, Picco G, Burchell JM, Taylor-Papadimitriou J, Reis CA, Almeida R, Mandel U, Clausen H, Söderberg O, David L.

J Cell Mol Med. 2012 Jul;16(7):1474-84. doi: 10.1111/j.1582-4934.2011.01436.x.

14.

ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues.

Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA.

Front Biosci (Elite Ed). 2011 Jun 1;3:1443-55.

PMID:
21622148
15.

Transforming growth factor-β1 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells.

Beatson R, Sproviero D, Maher J, Wilkie S, Taylor-Papadimitriou J, Burchell JM.

Biotechnol Bioeng. 2011 Nov;108(11):2759-64. doi: 10.1002/bit.23217. Epub 2011 Jun 9.

PMID:
21618471
16.

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM.

Breast Cancer Res. 2011 Mar 8;13(2):R25. doi: 10.1186/bcr2841.

17.

PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.

Catchpole S, Spencer-Dene B, Hall D, Santangelo S, Rosewell I, Guenatri M, Beatson R, Scibetta AG, Burchell JM, Taylor-Papadimitriou J.

Int J Oncol. 2011 May;38(5):1267-77. doi: 10.3892/ijo.2011.956. Epub 2011 Feb 28.

PMID:
21369698
18.

T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients.

Coleman JA, Correa I, Cooper L, Bohnenkamp HR, Poulsom R, Burchell JM, Taylor-Papadimitriou J.

Int J Cancer. 2011 May 1;128(9):2114-24. doi: 10.1002/ijc.25792. Epub 2011 Feb 11.

19.

MUC1 immunotherapy.

Beatson RE, Taylor-Papadimitriou J, Burchell JM.

Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17. Review.

PMID:
20635898
20.

Over-expression of ST3Gal-I promotes mammary tumorigenesis.

Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, Mandel U, Dell A, Pinder S, Taylor-Papadimitriou J, Burchell J.

Glycobiology. 2010 Oct;20(10):1241-50. doi: 10.1093/glycob/cwq085. Epub 2010 Jun 8.

21.

Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.

Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H.

Cancer Res. 2010 Feb 15;70(4):1306-13. doi: 10.1158/0008-5472.CAN-09-2893. Epub 2010 Feb 2.

22.

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.

Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM.

Br J Cancer. 2009 Jun 2;100(11):1746-54. doi: 10.1038/sj.bjc.6605083. Epub 2009 May 12.

23.

Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells.

Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J, Burchell JM.

Breast Cancer Res. 2008;10(3):R52. doi: 10.1186/bcr2106. Epub 2008 Jun 9.

24.

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.

Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, Maher J.

J Immunol. 2008 Apr 1;180(7):4901-9.

25.

Immunisation with 'naïve' syngeneic dendritic cells protects mice from tumour challenge.

Grimshaw MJ, Papazisis K, Picco G, Bohnenkamp H, Noll T, Taylor-Papadimitriou J, Burchell J.

Br J Cancer. 2008 Feb 26;98(4):784-91. doi: 10.1038/sj.bjc.6604221. Epub 2008 Feb 5.

26.

Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles.

Paul S, Geist M, Dott K, Snary D, Taylor-Papadimitriou J, Acres B, Silvestre N, Kieny MP, Balloul JM.

Viral Immunol. 2007 Dec;20(4):664-71.

PMID:
18158739
27.

Sialyl-Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: a mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I.

Julien S, Grimshaw MJ, Sutton-Smith M, Coleman J, Morris HR, Dell A, Taylor-Papadimitriou J, Burchell JM.

J Immunol. 2007 Nov 1;179(9):5701-10.

28.
29.

Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells.

Napoletano C, Rughetti A, Agervig Tarp MP, Coleman J, Bennett EP, Picco G, Sale P, Denda-Nagai K, Irimura T, Mandel U, Clausen H, Frati L, Taylor-Papadimitriou J, Burchell J, Nuti M.

Cancer Res. 2007 Sep 1;67(17):8358-67.

30.

Functional analysis of the transcription repressor PLU-1/JARID1B.

Scibetta AG, Santangelo S, Coleman J, Hall D, Chaplin T, Copier J, Catchpole S, Burchell J, Taylor-Papadimitriou J.

Mol Cell Biol. 2007 Oct;27(20):7220-35. Epub 2007 Aug 20.

31.

Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases.

Barrett A, Santangelo S, Tan K, Catchpole S, Roberts K, Spencer-Dene B, Hall D, Scibetta A, Burchell J, Verdin E, Freemont P, Taylor-Papadimitriou J.

Int J Cancer. 2007 Jul 15;121(2):265-75.

32.

PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.

Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y.

Mol Cell. 2007 Mar 23;25(6):801-12. Epub 2007 Mar 15.

33.

Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.

Tarp MA, Sørensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H.

Glycobiology. 2007 Feb;17(2):197-209. Epub 2006 Oct 18.

PMID:
17050588
34.

Characterization of integrin and anchorage dependence in mammary epithelial cells following c-erbB2-induced epithelial-mesenchymal transition.

Jenndahl LE, Taylor-Papadimitriou J, Baeckstrom D.

Tumour Biol. 2006;27(1):50-8. Epub 2005 Dec 8.

PMID:
16340250
35.

The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.

Sewell R, Bäckström M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gätgens J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J.

J Biol Chem. 2006 Feb 10;281(6):3586-94. Epub 2005 Nov 30.

36.

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

Sørensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H.

Glycobiology. 2006 Feb;16(2):96-107. Epub 2005 Oct 5.

PMID:
16207894
37.

Gene expression changes induced by a recombinant E1-/E3- adenovirus type 5 vector in human mammary epithelial cells.

Scibetta AG, Copier J, Barrett A, Chaplin T, Taylor-Papadimitriou J.

Intervirology. 2005;48(6):350-61.

PMID:
16024939
38.

Mucin based breast cancer vaccines.

Miles DW, Taylor-Papadimitriou J.

Expert Opin Investig Drugs. 1998 Nov;7(11):1865-77.

PMID:
15991935
39.

Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells.

Rughetti A, Pellicciotta I, Biffoni M, Bäckström M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC, Burchell JM, Frati L, Taylor-Papadimitriou J, Nuti M.

J Immunol. 2005 Jun 15;174(12):7764-72.

40.

Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.

Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T.

Cell Immunol. 2004 Sep-Oct;231(1-2):112-25. Epub 2005 Feb 8.

PMID:
15919376
41.

Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.

Bohnenkamp HR, Burchell JM, Taylor-Papadimitriou J, Noll T.

J Immunol Methods. 2004 Nov;294(1-2):67-80.

PMID:
15604017
42.

Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice.

Mungul A, Cooper L, Brockhausen I, Ryder K, Mandel U, Clausen H, Rughetti A, Miles DW, Taylor-Papadimitriou J, Burchell JM.

Int J Oncol. 2004 Oct;25(4):937-43.

PMID:
15375543
43.

Crystallization of an antitumour antibody SM3 complexed with a peptide epitope.

Dokurno P, Lally JM, Bates PA, Taylor-Papadimitriou J, Band HA, Snary D, Freemont PS.

Acta Crystallogr D Biol Crystallogr. 1997 Nov 1;53(Pt 6):780-1.

PMID:
15299868
44.

A short region of the promoter of the breast cancer associated PLU-1 gene can regulate transcription in vitro and in vivo.

Catteau A, Rosewell I, Solomon E, Taylor-Papadimitriou J.

Int J Oncol. 2004 Jul;25(1):5-16.

PMID:
15201984
45.

Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium.

Link T, Bäckström M, Graham R, Essers R, Zörner K, Gätgens J, Burchell J, Taylor-Papadimitriou J, Hansson GC, Noll T.

J Biotechnol. 2004 May 13;110(1):51-62.

PMID:
15099905
46.
47.

Joyce Taylor-Papadimitriou. Interview by Fiona Watt.

Taylor-Papadimitriou J.

J Cell Sci. 2004 Jan 26;117(Pt 3):371-2. No abstract available.

48.

PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis.

Madsen B, Tarsounas M, Burchell JM, Hall D, Poulsom R, Taylor-Papadimitriou J.

Chromosoma. 2003 Oct;112(3):124-32. Epub 2003 Sep 10.

PMID:
14579128
49.

Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer.

Madsen B, Spencer-Dene B, Poulsom R, Hall D, Lu PJ, Scott K, Shaw AT, Burchell JM, Freemont P, Taylor-Papadimitriou J.

Mech Dev. 2002 Dec;119 Suppl 1:S239-46.

50.

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2.

Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, Shearer M, Beuzeboc P, Van Belle S, Uzielly B, Pouillart P, Taylor-Papadimitriou J, Miles D.

J Biomed Biotechnol. 2003;2003(3):194-201.

Supplemental Content

Loading ...
Support Center